SIXTY-EIGHTH

ANNUAL MEETING

November 20–24, 2019 | astmh.org | ajtmh.org | #TropMed19 #IamTropMed

GAYLORD NATIONAL RESORT AND CONVENTION CENTER | NATIONAL HARBOR, MARYLAND, USA

ASTMH is an international society committed to equity and global impact through the treatment and prevention of tropical infectious diseases. Our diverse membership comes from more than 115 countries... we are committed to the open exchange of ideas, freedom of thought and expression, and productive scientific debate... open and diverse environment that is built on dignity and mutual respect for all. There is no discrimination based on personal attributes including but not limited to ethnicity, color, national origin, age, religion, socioeconomic status, disability, sexual orientation, gender, and gender identity or expression.

ASTMH is an international society committed to equity and global impact through the treatment and prevention of tropical infectious diseases. Our diverse membership comes from more than 115 countries... we are committed to the open exchange of ideas, freedom of thought and expression, and productive scientific debate... open and diverse environment that is built on dignity and mutual respect for all. There is no discrimination based on personal attributes including but not limited to ethnicity, color, national origin, age, religion, socioeconomic status, disability, sexual orientation, gender, and gender identity or expression.

Supplement to
The American Journal of Tropical Medicine and Hygiene
the leishmanin skin test; microscopic identification of amastigotes from skin aspirates, biopsies and scrapings; culture; and molecular assays. We aim to determine optimal methods to accurately and efficiently diagnose TL to improve diagnostic stewardship. We searched five databases from inception to July 16, 2018 including Ovid MEDLINE, Embase, LILACS, Cochrane Library and Scopus with the following search terms: (“cutaneous leishmanial” OR “Cutaneous leishmanial” OR “Cutaneous leishmanial” OR “Cutaneous leishmanial” OR “Cutaneous leishmanial”) AND (diagnosis OR diagnostic accuracy OR sensitivity OR specificity OR standard OR test*) AND NOT (visceral*). All systematic reviews, diagnostic trials and observational studies were included. Titles, abstracts and full-texts are systematically double screened by two reviewers with a tertiary arbitrator. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Quality Assessment of Diagnostic Accuracy Studies (QUADAS) will be employed. 6745 papers were identified from the five databases and 1278 papers remained for abstract evaluation (3391 removed) after title screening, where non-human, non-TL, non-diagnostic and case report articles were excluded. Abstract and full-text screening will be conducted. Data will be extracted from full-texts and assessed using QUADAS for selection and information bias. Heterogeneity of the studies will be determined and meta-analysis performed as appropriate. TL cannot be distinguished from competing infectious etiologies clinically, thus necessitating confirmatory diagnostics. A knowledge synthesis of accurate diagnostic assays can provide insight into the optimal approach for TL confirmation and subsequently guide therapy.

1843

ETHNOPHARMACEUTICALS FOR THE TREATMENT OF NEW WORLD CUTANEOUS LEISHMANIASIS: A SYSTEMATIC REVIEW OF TOPICAL APPLICATION OF PEPPER AND ALLIUM

Anjola Ogunsina1, Ruwandi Kariyawasam2, Olamide Egbeawumi1, Sonia Igoanu3, Shvetla Bhasker1, Shareese Clarke1, Paul Dunn1, Avinash N. Mukkala1, David Harris1, Andrea K. Boggild1

1Tropical Disease Unit, Toronto General Hospital and University of Toronto, Toronto, ON, Canada; 2Institute of Medical Sciences, Department of Medicine, University of Toronto, Toronto, ON, Canada

New World Cutaneous Leishmaniasis (NWCL) is a neglected parasitic disease caused by members of the genus Leishmania primarily identified in Central and South America. Better drugs are urgently needed given the toxicity, expense and accessibility limits of first-line treatment options. Plant-based compounds with potential anti-leishmanial effects found in and around local endemic communities, particularly in and around the Amazon basin, present an opportunity to overcome the aforementioned therapeutic challenges, and many such interventions are supported by anecdotal evidence of efficacy. We aim to synthesize existing evidence around available ethnopharmaceuticals to promote drug discovery for the prevention and treatment of NWCL. PubMed (NCBI), Embase (OVID), Web of Science (BioSIS) and LILACS (VHL) were searched for from inception to July 26, 2018 using combinations of the search terms "cutaneous leishmaniasis" and "ethnopharmaceuticals". Iterative inclusion and exclusion of search terms was employed to maximize relevant article extraction. For the systematic review, we included molecular, mechanistic, and observational studies, case reports, case series, cohort studies, as well as clinical trials reporting therapeutic outcomes, if possible using the GRADE approach. A total of 13667 abstracts were retrieved, after which 7566 duplicates were removed. Of the remaining abstracts, 550 abstracts were included in the full text review, of which 176 (32%) abstracts highlighted New World species; 116 (66.0%), 33 (18.7%), and 27 (15.3%) abstracts pertained to L. amazonensis, members of Viannia subgenus, and other New World species, respectively. Of all the abstracts included in the full text review, 25 (4.5%) and 6 (1.1%) were identified for Piper spp., "Pepper" and Allium spp., "Garlic", respectively. Synthesizing the current evidence surrounding ethnopharmaceuticals for the treatment of NWCL may contribute to drug discovery pipelines and potentially lead to novel therapeutics, particularly those targeting the Viannia complex, where patients often develop more severe clinical manifestations.

1844

AN UPDATE ON THE ROLE OF WOUND CARE IN THE MANAGEMENT OF OLD WORLD CUTANEOUS LEISHMANIASIS

David Harris1, Ruwandi Kariyawasam2, Avinash N. Mukkala1, Christian Lecce3, Evan Beksk3, Andrea K. Boggild1

1Tropical Disease Unit, Toronto General Hospital and University of Toronto, Toronto, ON, Canada; 2Institute of Medical Sciences, Department of Medicine, University of Toronto, Toronto, ON, Canada

Old world cutaneous leishmaniasis (OWCL) typically presents as one or several chronic, infiltrative lesions on exposed parts of the body, and is treated pharmacologically to accelerate cure, reduce scarring, and to prevent parasite dissemination or relapse. Limited data support the role of local wound care for the management of OWCL, though the scope of such benefit and to which patient populations wound care should be applied remains undetermined due to the absence of synthesized data on the subject. We aim to synthesize the literature around the role of wound care in the management of OWCL to inform treatment guidelines and evidence-based therapeutic strategies. PubMed (OVID), Embase (OVID), and PubMed (NCBI) were searched from inception to February 2019 without language restriction using combinations of the search terms "leishmanial" and "wound care". The GRADE approach will be used to assess quality of studies reporting specific wound care interventions. 626 articles were identified with the initial search. After screening titles and abstracts, 315 articles were included in the review.
abstracts, 226 articles were selected for final review. 50 publications were specific for OWCL, 5 publications discussed wound care in both OWCL, and New World Cutaneous Leishmaniasis, and 58 publications were review articles. Study characteristics including number of participants, wound care strategy/ intervention (debridement and removal of crusts, occlusive dressings, cream/ointment containing silver, washing, topical antimicrobials), outcomes (cure, time to reepithelialization, induration/ reduction, scar formation-quality and cosmesis, safety/tolerability, costs, feasibility/accessibility), study location, and species identification, will be extracted from all eligible studies and analyzed. We will systematically map the literature and synthesize the current state of knowledge and topical wound-oriented management practices in OWCL in order to inform optimal adjunctive clinical approaches and guidelines. We will also identify knowledge gaps and potential prospective research questions to fill them.

1845

A SYSTEMATIC REVIEW OF WOUND CARE IN THE MANAGEMENT OF NEW WORLD CUTANEOUS LEISHMANIASIS

Ruwandri Kariyawasam1, David Harris2, Christian Lecce2, Avinash N. Mukkala3, Evan Belyky1, Andrea K. Boggs1

1Institute of Medical Sciences, Department of Medicine, University of Toronto, Toronto, ON, Canada; 2Tropical Disease Unit, Toronto General Hospital and University of Toronto, Toronto, ON, Canada

New world cutaneous leishmaniasis (NWCL) typically presents as one or several chronic, infiltrative lesions on exposed parts of the body, and is treated pharmacologically to accelerate cure, reduce scarring, and to prevent parasite dissemination or relapse. Limited data support the role of local wound care for the management of NWCL, though the scope of such benefit and to which patient populations wound care should be applied remains underdetermined due to the absence of synthesized data on the subject. We aim to synthesize the literature around the role of wound care in the management of NWCL to inform treatment guidelines and evidence-based therapeutic strategies. Medline (Ovid), Embase (Ovid), and PubMed (NCBI) were searched from inception to February 2019 without language restriction using combinations of the search terms “leishmaniasis” and “wound care”. The GRADE approach will be used to assess quality of studies reporting specific wound care interventions. 626 articles were identified with the initial search. After screening titles and abstracts, 226 articles were selected for final review. 113 publications were specific for NWCL, 5 publications discussed wound care in both NWCL and Old World Cutaneous Leishmaniasis, and 58 publications were review articles. Study characteristics including number of participants, wound care strategy/ intervention (debridement and removal of crusts, occlusive dressings, cream/ointment containing silver, washing, topical antimicrobials), outcomes (cure, time to reepithelialization, induration/ reduction, scar formation-quality and cosmesis, safety/tolerability, costs, feasibility/accessibility), study location, and species identification, will be extracted from all eligible studies and analyzed. We will systematically map the literature and synthesize the current state of knowledge and topical wound-oriented management practices in NWCL in order to inform optimal adjunctive clinical approaches and guidelines. We will also identify knowledge gaps and potential prospective research questions to fill them.

1846

PHENOTYPIC CHARACTERIZATION OF TRYPANOSOMES CELLS TREATED WITH TETRACYCLIC IRIDOID, ML F52 SUPPRESSION OF FLAGELLA ATTACHMENT PROTEINS

Georgina I. Djameh1, Thelma Tetteh2, Takuhiko Uto3, Frederick Ayerette1, Michael Amoa-Bosompem3, Faustus I. Azeyigbik4, Kofi D. Kwofe5, Tomoe Ohira6, Irene Ayl1, Shiro Iwanaga6, Nobuo Ohita6, Yukhiro Shoyama6, Mitsuoki Ohashi6

1Noguchi Memorial Institute for Medical Research, Accra, Ghana; 2Nagasaki International University, Nagasaki, Japan; 3Centre for Plant Medicine Research, Mampang-Akupem, Ghana; 4Tokyo Medical and Dental University, Tokyo, Japan

Despite the recent advances in drug research, finding a safe, effective, and easy to use chemotherapy for Human African Trypanosomiasis (HAT) remains a challenging task. This condition underlines the urgent necessity for the development of new drugs for the treatment of HAT. We previously identified the anti-tetrasporic activity of three novel tetracyclic iridoids; ML-2-3, Molucidin and ML-F52, isolated from Morinda lucida with IC50 values of 3.75μM, 1.27μM and 0.43μM, respectively. Immunohistochemistry (IHC) study showed that the compound significantly suppressed the expression of PfR2, which proceeded to the events of cell cycle alteration and apoptosis induction. Scanning Electron Microscopy revealed the severe phenotype of the flagella detached from the body of the parasite. Here we present a phenotypic characterization of ML-F52 treated trypanosomes in detail with analyzing the expression levels of Flagellum Attachment Zone (FAZ) filament proteins, Coiled-coil 2-domain containing protein (CC2D) and Flagella Attachment Zone protein 1 (FAZ-1) by IHC and Western blot assays. Immunohistochemistry study showed that ML-F52 significantly suppressed the expression of CC2D after 12 hours of post treatment whilst FAZ-1 did not show any significant suppression. After 24 hours of post treatment, cell length and FAZ length decreased with the emergence of cell containing detached flagella as compared to the control. Also, ML-F52 caused multinucleated phenotype and an increase in number of cells with only one or no visible kinetoplast. Western blot assay showed that CC2D expression was reduced more than approximately 80% by 12 hours post treatment and approximately 80% by 24 hours post treatment. Our findings suggested that ML-F52 might significantly inhibit the development and function of the flagellum.

1847

VISCERAL LEISHMANIASIS ELISA TESTING: EVALUATION OF SERIAL SERUM SAMPLES REVEALS AN UNANTICIPATED FINDING

Naomi E. Aronson1, Nancy Koles1, Saule Nursumkhambetova1, Rupal Modi1, Edgie Mark Co1, Dutchabong Shaw1, Robert DeFraites2, Ines Lakhil-Naouar1

1Uniformed Services University of the Health Sciences, Bethesda, MD, United States; 2William Beaumont Army Medical Center, El Paso, TX, United States; 3Walter Reed National Military Medical Center, Bethesda, MD, United States

Serologic testing for visceral leishmaniasis (VL) includes ELISA and immunochromatographic testing (ICT) methods. Generally antibody responses are reported to wane with time. 200 Iraq-deployed, healthy US servicemembers were enrolled in an asymptomatic VL surveillance study 2015-17 and ELISA testing of current, pre and post deployment sera was conducted. Their prior banked samples were requested from the Department of Defense Serum Repository; timepoints included entry to military service (accession), before deployment and upon return from Iraq. Serologic testing included a soluble Leishmania antigen-based ELISA using 1:400 serum dilution with positive ELISA results confirmed using a Leishmania Western Blot (WB, LD Bios, France). Additionally, post Iraq and enrollment sera were tested with rk39 ICT (Kilazar Detect, Inbios WA). Enrollment sera from seven subjects tested positive on ELISA (3.5%) with one WB confirmed; there were no reactive rk39 serologies. Post-deployment sera tested ELISA positive in 55 subjects (27.5%), 48%